Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Connolly, Stuart J., Crowther, Mark, Eikelboom, John W., Gibson, C. Michael, Curnutte, John T., Lawrence, John H., Yue, Patrick, Bronson, Michele D., Lu, Genmin, Conley, Pamela B., Verhamme, Peter, Schmidt, Jeannot, Middeldorp, Saskia, Cohen, Alexander T., Beyer-Westendorf, Jan, Albaladejo, Pierre, Lopez-Sendon, Jose, Demchuk, Andrew M., Pallin, Daniel J., Concha, Mauricio, Goodman, Shelly, Leeds, Janet, Souza, Sonia, Siegal, Deborah M., Zotova, Elena, Meeks, Brandi, Ahmad, Sadia, Nakamya, Juliet, Milling, Truman J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6699827/
https://ncbi.nlm.nih.gov/pubmed/30730782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1814051
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados